Ivosidenib is an inhibitor that targets IDH1. It’s used for people with AML who’ve had a relapse or don’t respond to treatment because of IDH1 mutations. It works by hitting the IDH1 mutation, which helps slow down cancer cell growth.
The tablets are available in 250 mg film-coated form and the recommended dose is 500 mg taken once daily via oral ingestion. One bottle has 60 pills, which is enough for a month if you take it as prescribed.
Reviews
There are no reviews yet.